We, and others, found that the use of such competitive antagonistic peptides, like apelin-F13A or MM54, indeed led to reduced vascularization (Figure S1C), attenuated tumor progression, and increased survival in GBM mouse models, as well as models of breast cancer [51,57,61]. Here, APLN is linked to glioblastoma.